EN | RU
EN | RU

Help Support

Back

Study evaluates safety and efficacy of glecaprevir/pibrentasvir in chronic hepatitis C adults

Study evaluates safety and efficacy of glecaprevir/pibrentasvir in chronic hepatitis C adults Study evaluates safety and efficacy of glecaprevir/pibrentasvir in chronic hepatitis C adults
Study evaluates safety and efficacy of glecaprevir/pibrentasvir in chronic hepatitis C adults Study evaluates safety and efficacy of glecaprevir/pibrentasvir in chronic hepatitis C adults

A multicenter, phase III, open-label (EXPEDITION-3) study was conducted to explore the safety and efficacy of glecaprevir/pibrentasvir therapy in treatment-naïve Brazilian adults having hepatitis C infection genotype 1-6. 

See All

Key take away

In treatment-naive adults suffering from hepatitis C infection with compensated liver cirrhosis (F4) or without liver cirrhosis (F2 or F3), glecaprevir/pibrentasvir was found to be well-tolerated and demonstrated high efficacy.

Background

A multicenter, phase III, open-label (EXPEDITION-3) study was conducted to explore the safety and efficacy of glecaprevir/pibrentasvir therapy in treatment-naïve Brazilian adults having hepatitis C infection genotype 1-6. 

Method

Participants without cirrhosis and with compensated cirrhosis were recruited in this study and were administered eight or 12 weeks of glecaprevir/pibrentasvir therapy respectively. Among the 100 patients enrolled, 75 received 8 weeks’ treatment, and 25 received 12 weeks’ treatment.

The rate of sustained virologic response after treatment was the primary outcome parameter and the on-treatment virologic failure and decline rates were the secondary outcome parameters. The baseline polymorphisms were precisely evaluated in nonstructural viral protein 5A (NS5A) and nonstructural viral protein 3 (NS3). Lab abnormalities and noxious events were also examined.

Result

The sustained virologic response at week 12 after the treatment was high (98/100 [98%]), as shown below:


Data are n (%) unless stated otherwise. 2-sided 95% CI based on the Wilson score method. CI, confidence interval; ITT, intention-to-treat; mITT, modified ITT; N/A, not applicable; OTVF, ontreatment virologic failure; SVR12, sustained virologic response at post-treatment Week 12

 

It remained elevated despite host factors and baseline viral factors including hepatitis C virus RNA levels, demographics, polymorphisms in NS3 and/or NS5A, genotype, and comorbidities.


Only 55% of patients were found to report ≥1 adverse event (the most common being headache [18%]). No serious adverse effect was found to be related to the drug. There were no hepatic decompensations reported.

Conclusion

Glecaprevir/pibrentasvir is a well-tolerated and efficient therapy in treatment-naïve Brazilian patients who are suffering from hepatitis C infection with compensated cirrhosis and without cirrhosis.

Source:

Annals of Hepatology

Article:

Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults with Chronic Hepatitis C Virus Genotypes 1-6 in Brazil

Authors:

Mario Peribañez-Gonzalez et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: